Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.…
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in London
Corvus Pharmaceuticals (NASDAQ: CRVS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 37 employees.
The shares were at 9.670 USD on 20 November 2026, up 27.2% over 52 weeks. Its 52-week range is 6.390 USD to 26.95 USD: the price is 64.1% below the high and 51.3% above the low.
Its market capitalisation is 815.69M USD.
Corvus Pharmaceuticals reports return on equity of -25.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 202.31M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 31.50 USD is 225.7% above the current price. The next earnings report is expected on 11 March 2027.